

Hong Kong

ADD (no change)


Consensus ratings*: Buy 33 Hold 3 Sell 0

Current price:	HK\$8.15
Target price:	HK\$15.13 ▲
Previous target:	HK\$13.60
Up/downside:	85.6%
CGI / Consensus:	19.8%
Reuters:	1093.HK
Bloomberg:	1093 HK
Market cap:	US\$12,394m
	HK\$97,256m
Average daily turnover:	US\$32.80m
	HK\$260.9m
Current shares o/s:	11,953m
Free float:	31.3%

*Source: Bloomberg

Key changes in this note

- FY22/FY23 NBP revenue cut by 30% and 40%, respectively.



Source: Bloomberg

Price performance	1M	3M	12M
Absolute (%)	9.2	-7.7	-17.8
Relative (%)	9.5	-5.5	5.3

Major shareholders	% held
Cai Dongchen	23.7

Analysts

Mark Po
 T (852) 3698 6318
 E markpo@chinastock.com.hk

CSPC Pharmaceutical

Oncology products have become a leading revenue growth driver

- NBP is one of CSPC's major nervous system disease products, and its sales have remained steady since the price cut in 2020. The lower price significantly improved its penetration in lower-tier cities, which helped offset the price cut impact.
- CSPC's oncology products have become a leading revenue growth driver with a resilient growth rate despite a high base of Rmb7.7bn in 2021. Mitoxantrone liposome, a new oncology drug, was approved in Jan 2022. Since mitoxantron is a broad anti-tumor drug, and its liposome formulation has shown increased efficacy and reduced cardiotoxicity, we believe it will see rapid growth, and we maintain our estimation for mitoxantron liposome's peak sales to exceed Rmb2bn. Duvelisib and BPI-1178 are expected to be approved this year, which will also contribute to revenue growth in the coming years.
- CSPC has established a leading position in nano-formulation. Amphotericin B liposome is expected to be approved in 2023. We are optimistic about the market potential of CSPC's approved Anfulike (amphotericin B cholesteryl sulfate complex for injection) and amphotericin B liposome. We believe they will lead revenue growth in the anti-infective product sector. CSPC is also leveraging its existing nanotechnology platform to carry out research on mRNA vaccines. CSPC's COVID-19 mRNA vaccine is expected to be approved in 2022. We recommend a follow-up to its clinical results readout.
- Given CSPC's deep innovative pipeline portfolio, which will create new revenue growth momentum, along with steady growth of its major existing drugs, we adjusted our 2022E, 2023E and 2024E EPS forecasts to Rmb0.507, 0.559, 0.611, respectively, similar to our previous projections. We reiterate our ADD rating with a new target price of 15.13, based on 25.5x 2022PER (CSPC's historical average PER).

Sales of nervous system disease products remain steady

NBP (butylphthalide soft capsules and butylphthalide and sodium chloride injection) is one of CSPC's major products. Sales of NBP have remained steady since the price cut through NRDL price negotiations in Dec, 2020. Owing to a 55.6% price cut for NBP capsules and a 51.3% price cut for NBP injections, its penetration into lower-tier cities significantly improved, so in 2021, NBP revenue still reached about Rmb6.5bn (26% of total revenue), similar to that in 2020. In 1Q22, sales of NBP saw high single-digit growth qoq. However, we expect sales of NBP to have been affected by the COVID-19 outbreak and city lockdowns. Therefore, we decreased our NBP 2022E sales forecast by 30%, and we expect 2022E NBP sales to remain at a similar level to that in 2021.

The patent for NBP injections expired in Jun 2022, and the patent for NBP capsules will expire in Dec 2023. Because butylphthalide has achieved annual sales of Rmb6.5bn, several pharmaceutical companies are planning to produce generic versions. So far, no reference drug for butylphthalide has been released by the Center for Drug Evaluation (CDE). We estimate that it will take about two years for a generic drug to pass the quality and efficacy consistency evaluation after the CDE releases a reference drug for butylphthalide in the future. Thus, we don't expect generic drug competition for NBP in the next three years to be a significant threat.

Financial Summary	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Revenue (Rmbm)	24,943	27,866	30,712	33,806	36,867
Operating EBITDA (Rmbm)	6,159	6,974	7,934	8,746	9,550
Net Profit (Rmbm)	5,298	5,771	6,281	6,903	7,521
Normalised EPS (Rmb)	0.44	0.48	0.53	0.58	0.63
Normalised EPS Growth	(26.5%)	8.9%	9.2%	9.9%	8.9%
FD Normalised P/E (x)	15.72	14.44	13.22	12.03	11.04
DPS (Rmb)	0.13	0.14	0.16	0.17	0.19
Dividend Yield	1.83%	2.03%	2.26%	2.49%	2.72%
EV/EBITDA (x)	12.14	10.43	8.69	7.65	6.76
P/FCFE (x)	25.79	21.68	17.22	15.70	13.81
Net Gearing	(37.8%)	(40.0%)	(43.6%)	(43.5%)	(43.9%)
P/BV (x)	3.73	3.21	2.59	2.26	1.98
ROE	26.0%	23.9%	21.7%	20.1%	19.1%
% Change In Normalised EPS Estimates			1.47%	(4.93%)	
Normalised EPS/consensus EPS (x)			1.02	0.99	0.95

SOURCES: CGIS RESEARCH, COMPANY DATA, BLOOMBERG

CSPC acquired Mingfule (recombinant human TNK tissue-type plasminogen activator for injection) by acquiring 51% equity interest in Recomgen Biotach. Mingfule is a third-generation specific thrombolytic drug, and the approved indication is for the treatment of thrombolysis in patients with acute myocardial infarction within six hours of onset. The Phase III trial of Mingfule is being conducted for the treatment of thrombolysis in cerebral infarction. Mingfule is expected to have synergy with NBP. By acquiring Mingfule, CSPC plans to further strengthen its leading position in thrombolysis treatment of acute myocardial infarction and offset the impact if generic butylphthalide is approved in the future.

Oncology portfolio now the leading revenue growth driver



Oncology drugs revenue exceeded the revenue of nervous system disease products in 2021, reaching Rmb7.7bn, representing a 22.5% yoy growth rate and 27.7% of total revenue. In 1Q22, the Company's oncology drugs had a 15% yoy growth rate. Since several of its new oncology drugs were approved or are expected to be approved in 2022, we forecast 11.4% yoy growth in sales of oncology drugs, taking into account the COVID-19 impact.

We think Duoenda (mitoxantrone hydrochloride liposome), which was approved by the NMPA in Jan 2022 for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL), will be a new revenue growth driver in the coming years. Mitoxantron is a broad-spectrum anti-tumor drug with major indications, including malignant lymphoma, breast cancer and acute leukemia, and it has also shown efficacy in several types of solid cancer. Mitoxantrone liposome can significantly reduce cardiotoxicity, and CSPC is conducting clinical trials to expand its indications, so we maintain our peak sales estimation, which is over Rmb2bn. In addition, Copiktra/Duvelisib capsules obtained drug registration approval in Mar 2022 for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL), and BPI-7711, a third generation EGFR-TKI inhibitor, are expected to be approved in 2022.

Leading nanotechnology platform and a developing focus on a nucleic acid drug delivery platform

CSPC has already established a leading position with its nanotechnology platform. It has successfully developed four key nano-formulation drugs. Duomeisu (Doxorubicin hydrochloride liposome) achieved sales of Rmb2.8bn in 2021, and given the rearrangement of its sales team, we expect it to achieve 13.0% yoy growth in 2022E. Amphotericin B liposome and Irinotecan liposome are expected to be approved in 2023. Nano-formulation technology has great application potential, especially in anti-tumor drug formulation, since it can increase the accessibility of drugs to tumour tissue and reduce side effects. CSPC has also leveraged its existing nanotechnology platform to carry out research on mRNA vaccines. Its COVID-19 mRNA vaccine is expected to be approved in 2022. We recommend a follow-up to its clinical results readout.

BY THE NUMBERS

P/BV vs ROE

12-mth Fwd FD Normalised P/E vs FD Normalised EPS Growth


Profit & Loss

(Rmbm)	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Total Net Revenues	24,943	27,866	30,712	33,806	36,867
Gross Profit	18,686	21,134	22,664	24,948	27,207
Operating EBITDA	6,159	6,974	7,934	8,746	9,550
Depreciation And Amortisation	(686)	(726)	(818)	(913)	(1,007)
Operating EBIT	5,472	6,248	7,116	7,833	8,543
Financial Income/(Expense)	(12)	(8)	72	82	95
Pretax Income/(Loss) from Assoc.	14	22	64	69	75
Non-Operating Income/(Expense)	917	584	326	359	391
Profit Before Tax (pre-EI)	6,391	6,847	7,578	8,344	9,103
Exceptional Items					
Pre-tax Profit	6,391	6,847	7,578	8,344	9,103
Taxation	(1,162)	(1,159)	(1,416)	(1,559)	(1,701)
Exceptional Income - post-tax					
Profit After Tax	5,229	5,688	6,162	6,784	7,402
Minority Interests	69	83	119	119	119
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Preference Dividends (Australia)					
Net Profit	5,298	5,771	6,281	6,903	7,521
Normalised Net Profit	5,229	5,688	6,162	6,784	7,402
Fully Diluted Normalised Profit	5,298	5,771	6,281	6,903	7,521

Cash Flow

(Rmbm)	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
EBITDA	6,159	6,974	7,934	8,746	9,550
Cash Flow from Invt. & Assoc.					
Change In Working Capital	299	(1,228)	(39)	(235)	(168)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow					
Net Interest (Paid)/Received	(12)	(8)	0	0	0
Tax Paid	(1,162)	(1,159)	(1,416)	(1,559)	(1,701)
Cashflow From Operations	5,283	4,579	6,479	6,952	7,681
Capex	(1,045)	(1,592)	(1,592)	(1,592)	(1,592)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(1,084)	955	(64)	(69)	(75)
Cash Flow From Investing	(2,130)	(637)	(1,656)	(1,661)	(1,667)
Debt Raised/(repaid)	76	(99)	0	0	0
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(1,528)	(1,691)	(1,877)	(2,070)	(2,262)
Preferred Dividends					
Other Financing Cashflow	(19)	(407)	0	0	0
Cash Flow From Financing	(1,471)	(2,197)	(1,877)	(2,070)	(2,262)
Total Cash Generated	1,683	1,745	2,946	3,221	3,753
Free Cashflow To Equity	3,230	3,843	4,823	5,291	6,014
Free Cashflow To Firm	3,166	3,949	4,823	5,291	6,014

SOURCES: CGIS RESEARCH, COMPANY DATA, BLOOMBERG

BY THE NUMBERS... cont'd
Balance Sheet

(Rmbm)	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Total Cash And Equivalents	8,831	10,727	14,376	16,475	18,966
Total Debtors	11	10	9	10	10
Inventories	1,861	2,480	2,709	3,003	3,227
Total Other Current Assets	5,218	7,119	7,662	8,186	8,847
Total Current Assets	15,921	20,337	24,756	27,674	31,049
Fixed Assets	7,770	8,529	10,875	13,314	15,846
Total Investments	833	943	1,008	1,077	1,151
Intangible Assets	659	618	682	749	816
Total Other Non-Current Assets	4,886	4,314	4,314	4,314	4,314
Total Non-current Assets	14,149	14,405	16,879	19,453	22,127
Short-term Debt	99	0	0	0	0
Current Portion of Long-Term Debt					
Total Creditors	4,759	6,162	6,894	7,478	8,195
Other Current Liabilities	1,444	1,064	1,064	1,064	1,064
Total Current Liabilities	6,302	7,226	7,958	8,541	9,259
Total Long-term Debt	0	0	0	0	0
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	667	687	687	687	687
Total Non-current Liabilities	667	687	687	687	687
Total Provisions	0	0	0	0	0
Total Liabilities	6,969	7,913	8,645	9,229	9,946
Shareholders' Equity	22,332	25,987	32,030	36,818	42,032
Minority Interests	769	842	961	1,080	1,199
Total Equity	23,101	26,828	32,990	37,898	43,230

Key Ratios

	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Revenue Growth	12.9%	11.7%	10.2%	10.1%	9.1%
Operating EBITDA Growth	21.9%	13.2%	13.8%	10.2%	9.2%
Operating EBITDA Margin	24.7%	25.0%	25.8%	25.9%	25.9%
Net Cash Per Share (Rmb)	0.73	0.90	1.21	1.38	1.59
BVPS (Rmb)	1.87	2.17	2.69	3.09	3.53
Gross Interest Cover	447.4	815.3	N/A	N/A	N/A
Effective Tax Rate	18.2%	16.9%	18.7%	18.7%	18.7%
Net Dividend Payout Ratio	28.8%	29.3%	29.9%	30.0%	30.1%
Accounts Receivables Days	0.15	0.13	0.11	0.10	0.10
Inventory Days	128.6	117.7	117.7	117.7	118.0
Accounts Payables Days	67.72	72.82	72.82	72.82	73.02
ROIC (%)	39.8%	44.0%	44.9%	42.8%	40.6%
ROCE (%)	25.6%	25.0%	24.0%	22.3%	21.3%
Return On Average Assets	18.6%	17.6%	15.9%	15.1%	14.6%

Key Drivers

	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Nervous system disease products revenue growth (%)	1.5%	1.8%	1.4%	4.5%	2.6%
Oncology products revenue growth (%)	29.0%	22.5%	11.4%	10.0%	9.4%
Anti-infective products revenue growth (%)	-7.9%	8.9%	11.7%	7.2%	9.4%

SOURCES: CGIS RESEARCH, COMPANY DATA, BLOOMBERG

DISCLAIMER

The content of this report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by and belongs to China Galaxy International Securities (Hong Kong) Co., Limited ("China Galaxy International"), and is distributed by CGS-CIMB pursuant to an arrangement between China Galaxy International and CGS-CIMB.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CGS-CIMB.

The information contained in this research report is prepared from data believed to be correct and reliable at the time of issue of this report.

China Galaxy International may or may not issue regular reports on the subject matter of this report at any frequency and may cease to do so or change the periodicity of reports at any time. Neither China Galaxy International nor CGS-CIMB is under any obligation to update this report in the event of a material change to the information contained in this report. Neither China Galaxy International nor CGS-CIMB has any and will accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant, (ii) ensure that the content of this report constitutes all the information a prospective investor may require, (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, China Galaxy International, CGS-CIMB and their respective affiliates and related persons including China Galaxy International Financial Holdings Limited ("CGIFHL") and CIMB Group Sdn. Bhd. ("CIMBG") and their respective related corporations (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. In particular, China Galaxy International and CGS-CIMB disclaim all responsibility and liability for the views and opinions set out in this report.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from China Galaxy International's research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of CGS-CIMB or China Galaxy International or any of their respective affiliates (including CGIFHL, CIMBG and their respective related corporations) to any person to buy or sell any investments.

CGS-CIMB and/or China Galaxy International and/or their respective affiliates and related corporations (including CGIFHL, CIMBG and their respective related corporations), their respective directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CGS-CIMB and/or China Galaxy International, and/or their respective affiliates and their respective related corporations (including CGIFHL, CIMBG and their respective related corporations) do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

CGS-CIMB and/or China Galaxy International and/or their respective affiliates (including CGIFHL, CIMBG and their respective related corporations) may enter into an agreement with the company(ies) covered in this report relating to the production of research reports. CGS-CIMB and/or China Galaxy International may disclose the contents of this report to the company(ies) covered by it and may have amended the contents of this report following such disclosure.

The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report. The analyst(s) who prepared this research report is prohibited from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company. Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/her coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations and the research personnel involved in the preparation of this report may also participate in the solicitation of the businesses as described above. In reviewing this research report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.

The term "China Galaxy International" shall, unless the context otherwise requires, mean China Galaxy International and its affiliates, subsidiaries and related companies. The term "CGS-CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case except as otherwise stated herein, CGS-CIMB Securities International Pte. Ltd. and its affiliates, subsidiaries and related corporations.

CGS-CIMB

Country	CGS-CIMB Entity	Regulated by
Hong Kong	CGS-CIMB Securities (Hong Kong) Limited	Securities and Futures Commission Hong Kong
India	CGS-CIMB Securities (India) Private Limited	Securities and Exchange Board of India (SEBI)
Indonesia	PT CGS-CIMB Sekuritas Indonesia	Financial Services Authority of Indonesia
Malaysia	CGS-CIMB Securities Sdn. Bhd.	Securities Commission Malaysia
Singapore	CGS-CIMB Securities (Singapore) Pte. Ltd.	Monetary Authority of Singapore
South Korea	CGS-CIMB Securities (Hong Kong) Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Thailand	CGS-CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

(i) As of June 30, 2022 Galaxy International Securities/ China Galaxy International Finance (Hong Kong) Co., Limited, one of the subsidiaries of China Galaxy International Financial Holdings Limited, has financial interests of more than 1% in the securities (which may include but not limited to shares, warrants, call warrants and/ or other derivatives) in the following or companies covered or recommended in this report:

(a)

(ii) As of June 30, 2022 CGS-CIMB has a proprietary position in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a)

(iii) As of July 6, 2022, the analyst(s) who prepared this report, and the associate(s), has / have an interest in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a)

(a)

This report does not purport to contain all the information that a prospective investor may require. CGS-CIMB, China Galaxy International and their respective affiliates (including CGIFHL, CIMBG and their related corporations) do not make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. None of CGS-CIMB, China Galaxy International and their respective affiliates and related persons (including CGIFHL, CIMBG and their related corporations) shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CGS-CIMB's and its affiliates' (including CGIFHL's, CIMBG's and their respective related corporations') clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments or any derivative instrument, or any rights pertaining thereto.

Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this research report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

Restrictions on Distributions

Australia: Despite anything in this report to the contrary, this research is issued by China Galaxy International and provided in Australia by CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. You represent and warrant that if you are in Australia, you are a "wholesale client". This research is of a general nature only and has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited do not hold, and are not required to hold an Australian financial services license. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited rely on "passporting" exemptions for entities appropriately licensed by the Monetary Authority of Singapore (under ASIC Class Order 03/1102) and the Securities and Futures Commission in Hong Kong (under ASIC Class Order 03/1103).

Canada: This research report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For any research report distributed by CIBC, further disclosures related to CIBC conflicts of interest can be found at <https://researchcentral.cibcwm.com>.

China: For the purpose of this report, the People's Republic of China ("PRC") does not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region or Taiwan. The distributor of this report has not been approved or licensed by the China Securities Regulatory Commission or any other relevant regulatory authority or governmental agency in the PRC. This report contains only marketing information. The distribution of this report is not an offer to buy or sell to any person within or outside PRC or a solicitation to any person within or outside of PRC to buy or sell any instruments described herein. This report is being issued outside the PRC to a limited number of institutional investors and may not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose.

France: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

Germany: This report is only directed at persons who are professional investors as defined in sec 31a(2) of the German Securities Trading Act (WpHG). This publication constitutes research of a non-binding nature on the market situation and the investment instruments cited here at the time of the publication of the information.

The current prices/yields in this issue are based upon closing prices from Bloomberg as of the day preceding publication. Please note that neither the

German Federal Financial Supervisory Agency (BaFin), nor any other supervisory authority exercises any control over the content of this report.

Hong Kong: This report is issued and distributed in Hong Kong by CGS-CIMB Securities (Hong Kong) Limited (“CHK”) which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CGS-CIMB Securities (Hong Kong) Limited. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its opinion or the information in this research report.

India:

This report is issued by China Galaxy International and distributed in India by CGS-CIMB Securities (India) Private Limited (“CGS-CIMB India”). CGS-CIMB India is a subsidiary of CGS-CIMB Securities International Pte. Ltd. which in turn is a 50:50 joint venture company of CGIFHL and CIMBG. The details of the members of the group of companies of CGS-CIMB can be found at www.cgs-cimb.com, CGIFHL at www.chinastock.com.hk/en/ACG/ContactUs/index.aspx and CIMBG at www.cimb.com/en/who-we-are.html. CGS-CIMB India is registered with the National Stock Exchange of India Limited and BSE Limited as a trading and clearing member (Merchant Banking Number: INM000012037) under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992. In accordance with the provisions of Regulation 4(g) of the Securities and Exchange Board of India (Investment Advisers) Regulations, 2013, CGS-CIMB India is not required to seek registration with the Securities and Exchange Board of India (“SEBI”) as an Investment Adviser. CGS-CIMB India is registered with SEBI (SEBI Registration Number: INZ000209135) as a Research Analyst (INH000000669) pursuant to the SEBI (Research Analysts) Regulations, 2014 (“Regulations”).

This report does not take into account the particular investment objectives, financial situations, or needs of the recipients. It is not intended for and does not deal with prohibitions on investment due to law/jurisdiction issues etc. which may exist for certain persons/entities. Recipients should rely on their own investigations and take their own professional advice before investment.

The report is not a “prospectus” as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of CGS-CIMB India and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by CGS-CIMB India or its affiliates.

CGS-CIMB India does not have actual / beneficial ownership of 1% or more securities of the subject company in this research report, at the end of the month immediately preceding the date of publication of this research report. However, since affiliates of CGS-CIMB India are engaged in the financial services business, they might have in their normal course of business financial interests or actual / beneficial ownership of one per cent or more in various companies including the subject company in this research report.

CGS-CIMB India or its associates, may: (a) from time to time, have long or short position in, and buy or sell the securities of the subject company in this research report; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company in this research report or act as an advisor or lender/borrower to such company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

CGS-CIMB India, its associates and the analyst engaged in preparation of this research report have not received any compensation for investment banking, merchant banking or brokerage services from the subject company mentioned in the research report in the past 12 months.

CGS-CIMB India, its associates and the analyst engaged in preparation of this research report have not managed or co-managed public offering of securities for the subject company mentioned in the research report in the past 12 months. The analyst from CGS-CIMB India engaged in preparation of this research report or his/her relative (a) do not have any financial interests in the subject company mentioned in this research report; (b) do not own 1% or more of the equity securities of the subject company mentioned in the research report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the research report.

Indonesia: This report is issued by China Galaxy International and distributed by PT CGS-CIMB Sekuritas Indonesia (“CGS-CIMB Indonesia”). The views and opinions in this research report are not our own but of China Galaxy International as of the date hereof and are subject to change. CGS-CIMB Indonesia has no obligation to update the opinion or the information in this research report. This report is for private circulation only to clients of CGS-CIMB Indonesia. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable Indonesian capital market laws and regulations.

This research report is not an offer of securities in Indonesia. The securities referred to in this research report have not been registered with the Financial Services Authority (Otoritas Jasa Keuangan) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market law and regulations.

Ireland: CGS-CIMB is not an investment firm authorised in the Republic of Ireland and no part of this document should be construed as CGS-CIMB acting as, or otherwise claiming or representing to be, an investment firm authorised in the Republic of Ireland.

Malaysia: This report is distributed in Malaysia by CGS-CIMB Securities Sdn. Bhd. (“CGS-CIMB Malaysia”) solely for the benefit of and for the exclusive use of our clients. Recipients of this report are to contact CGS-CIMB Malaysia, at Level 29, Menara Bumiputra-Commerce, No. 11, Jalan Raja Laut, 50350 Kuala Lumpur, Malaysia, in respect of any matters arising from or in connection with this report. CGS-CIMB Malaysia has no obligation to update, revise or reaffirm its opinion or the information in this research report after the date of this report. CGS-CIMB Malaysia may act or acts as a market maker in the capital market products of the following companies:

UEM EDGENTA BERHAD, EASTERN & ORIENTAL BERHAD, UEM SUNRISE BERHAD, AXIATA GROUP BERHAD, KERJAYA PROSPEK GROUP BERHAD, RANHILL UTILITIES BERHAD, TELEKOM MALAYSIA BERHAD, MATRIX CONCEPTS HOLDINGS BERHAD, SPORTS TOTO BERHAD, KAWAN FOOD BERHAD, DRB-HICOM BERHAD, TALIWORKS CORPORATION BERHAD, ASTRO MALAYSIA HOLDINGS BERHAD, TENAGA NASIONAL BERHAD, MALAYAN BANKING BERHAD, IOI CORPORATION BERHAD, GENTING BERHAD, UNISEM (M) BERHAD, FGV HOLDINGS BERHAD, YINSON HOLDINGS BERHAD.

New Zealand: In New Zealand, this report is for distribution only to persons who are wholesale clients pursuant to section 5C of the Financial Advisers Act 2008.

Singapore: This report is issued by China Galaxy International and distributed by CGS-CIMB Securities (Singapore) Pte Ltd (“CGS-CIMB Singapore”). CGS-CIMB Singapore is a capital markets services licensee under the Securities and Futures Act (Chapter 289). Accordingly, it is exempted from the requirement to hold a financial adviser’s licence under the Financial Advisers Act, Cap 110 (“FAA”) for advising on investment products, by issuing or promulgating research analyses or research reports, whether in electronic, print or other form. Accordingly CGS-CIMB Singapore is subject to the applicable rules under the FAA unless it is able to avail itself to any prescribed exemptions.

Recipients of this report are to contact CGS-CIMB Singapore, 10 Marina Boulevard, Marina Bay Financial Centre Tower 2, #09-01, Singapore 018983 in respect of any matters arising from, or in connection with this report. CGS-CIMB Singapore has no obligation to update the opinion or the information in this research report. This publication is strictly confidential and is for private circulation only. If you have not been sent this report by CGS-CIMB Singapore directly, you may not rely, use or disclose to anyone else this report or its contents.

If the recipient of this research report is not an accredited investor, expert investor or institutional investor, CGS-CIMB Singapore accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. If the recipient is an accredited investor, expert investor or institutional investor, the recipient is deemed to acknowledge that CGS-CIMB Singapore is exempt from certain requirements under the FAA and its attendant regulations, and as such, is exempt from complying with the following :

- (a) Section 25 of the FAA (obligation to disclose product information);
- (b) Section 27 (duty not to make recommendation with respect to any investment product without having a reasonable basis where you may be reasonably expected to rely on the recommendation) of the FAA;
- (c) MAS Notice on Information to Clients and Product Information Disclosure [Notice No. FAA-N03];
- (d) MAS Notice on Recommendation on Investment Products [Notice No. FAA-N16];
- (e) Section 36 (obligation on disclosure of interest in securities), and
- (f) any other laws, regulations, notices, directive, guidelines, circulars and practice notes which are relates to the above, to the extent permitted by applicable laws, as may be amended from time to time, and any other laws, regulations, notices, directive, guidelines, circulars, and practice notes as we may notify you from time to time. In addition, the recipient who is an accredited investor, expert investor or institutional investor acknowledges that a CGS-CIMB Singapore is exempt from Section 27 of the FAA, the recipient will also not be able to file a civil claim against CGS-CIMB Singapore for any loss or damage arising from the recipient’s reliance on any recommendation made by CGS-CIMB Singapore which would otherwise be a right that is available to the recipient under Section 27 of the FAA.

CGS-CIMB Singapore, its affiliates and related corporations, their directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CGS-CIMB Singapore, its affiliates and its related corporations do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

As of July 6, 2022, CGS-CIMB Singapore does not have a proprietary position in the recommended specified products in this report.

CGS-CIMB Singapore makes a market on the specified products of .

CGS-CIMB Singapore does not make a market on other securities mentioned in the report.

Chan Swee Liang Carolina, the Group Chief Executive Officer of the CGS-CIMB group of companies (in which CGS-CIMB Singapore is a member) is an independent non-executive director of City Developments Limited as of 29 Dec 2020. CGS-CIMB Singapore is of the view that this does not create any conflict of interest that may affect the ability of the analyst [or CGS-CIMB Singapore] to offer independent and unbiased analyses and recommendations.

Chan Swee Liang Carolina, the Group Chief Executive Officer of the CGS-CIMB group of companies (in which CGS-CIMB Singapore is a member) is an independent non-executive director of Genting Singapore PLC as of 1 May 2018. CGS-CIMB Singapore is of the view that this does not create any conflict of interest that may affect the ability of the analyst [or CGS-CIMB Singapore] to offer independent and unbiased analyses and recommendations.

South Korea: This report is issued by China Galaxy International and distributed in South Korea by CGS-CIMB Securities (Hong Kong) Limited, Korea Branch (“CGS-CIMB Korea”) which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. In South Korea, this report is for distribution only to professional investors under Article 9(5) of the Financial Investment Services and Capital Market Act of Korea (“FSCMA”).

Spain: This document is a research report and it is addressed to institutional investors only. The research report is of a general nature and not personalised and does not constitute investment advice so, as the case may be, the recipient must seek proper advice before adopting any investment decision. This document does not constitute a public offering of securities.

CGS-CIMB is not registered with the Spanish Comision Nacional del Mercado de Valores to provide investment services.

Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

Switzerland: This report has not been prepared in accordance with the recognized self-regulatory minimal standards for research reports of banks

issued by the Swiss Bankers' Association (Directives on the Independence of Financial Research).

Thailand: This report is issued and distributed by CGS-CIMB Securities (Thailand) Co. Ltd. ("CGS-CIMB Thailand") based upon sources believed to be reliable (but their accuracy, completeness or correctness is not guaranteed). The statements or expressions of opinion herein were arrived at after due and careful consideration for use as information for investment. Such opinions are subject to change without notice and CGS-CIMB Thailand has no obligation to update its opinion or the information in this research report.

CGS-CIMB Thailand may act or acts as Market Maker, and issuer and offeror of Derivative Warrants and Structured Note which may have the following securities as its underlying securities. Investors should carefully read and study the details of the derivative warrants in the prospectus before making investment decisions.

AAV, ACE, ADVANC, AEONTS, AMATA, AOT, AP, BAM, BANPU, BBL, BCH, BCP, BCPG, BDMS, BEC, BEM, BGRIM, BH, BJC, BTS, CBG, CENTEL, CHG, CK, CKP, COM7, CPALL, CPF, CPN, CRC, DELTA, DOHOME, DTAC, EA, EGCO, ESSO, GLOBAL, GPSC, GULF, GUNKUL, HANA, HMPRO, ICHI, INTUCH, IRPC, IVL, JAS, JMART, JMT, KBANK, KCE, KKP, KTB, KTC, LH, MAJOR, MEGA, MINT, MTC, NRF, OR, ORI, OSP, PLANB, PRM, PSL, PTG, PTL, PTT, PTTEP, PTTGC, QH, RATCH, RBF, RS, SAWAD, SCB, SCC, SCGP, SINGER, SPALI, SPRC, STA, STEC, STGT, SUPER, SYNEX, TASCO, TCAP, THANI, TISCO, TKN, TOP, TQM, TRUE, TTB, TU, TVO, VGI, WHA

Corporate Governance Report:

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CGS-CIMB Thailand does not confirm nor certify the accuracy of such survey result.

Score Range:	90 - 100	80 – 89	70 - 79	Below 70	No Survey Result
Description:	Excellent	Very Good	Good	N/A	N/A

United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

United Kingdom and European Economic Area (EEA): In the United Kingdom and European Economic Area, this material is also being distributed by CGS-CIMB Securities (UK) Limited ("CGS-CIMB UK"). CGS-CIMB UK is authorized and regulated by the Financial Conduct Authority and its registered office is at 53 New Broad Street, London EC2M 1JJ. The material distributed by CGS-CIMB UK has been prepared in accordance with CGS-CIMB's policies for managing conflicts of interest arising as a result of publication and distribution of this material. This material is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of CGS-CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (c) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom subject to relevant regulation in each jurisdiction, material(all such persons together being referred to as "relevant persons"). This material is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

This material is categorised as non-independent for the purposes of CGS-CIMB UK and therefore does not provide an impartial or objective assessment of the subject matter and does not constitute independent research. Consequently, this material has not been prepared in accordance with legal requirements designed to promote the independence of research and will not be subject to any prohibition on dealing ahead of the dissemination of research. Therefore, this material is considered a marketing communication.

United States: This research report is issued by China Galaxy International and distributed in the United States of America by CGS-CIMB Securities (USA) Inc, a U.S. registered broker-dealer and a related company of CGS-CIMB Securities (Singapore) Pte Ltd, PT CGS-CIMB Sekuritas Indonesia, CGS-CIMB Securities (Thailand) Co. Ltd, CGS-CIMB Securities (Hong Kong) Limited, CGS-CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CGS-CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc.

CGS-CIMB Securities (USA) Inc. has managed or co-managed a public offering of securities for in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not managed or co-managed a public offering of any of the securities mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. has received compensation for investment banking services from in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not received compensation for investment banking services from any of the company mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. expects to receive or intend to seek compensation for investment banking services from within the next 3 months.

CGS-CIMB Securities (USA) Inc. neither expects to receive nor intends to seek compensation for investment banking services from any of the company mentioned within the next 3 months.

As of the end of the month immediately preceding the date of publication of this report, CGS-CIMB Securities (USA) Inc. beneficially owns 1% or more

of any class of common equity securities of .

Other jurisdictions: In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Distribution of stock ratings and investment banking clients for quarter ended on 31 Mar 2022		
632 companies under coverage for quarter ended on 31 Mar 2022		
	Rating Distribution (%)	Investment Banking clients (%)
Add	70.3%	0.8%
Hold	22.0%	0.0%
Reduce	7.8%	0.2%

Spitzer Chart for stock being researched (2 year data)

CSPC Pharmaceutical (1093 HK)

RECOMMENDATION FRAMEWORK

Stock Ratings Definition:

Add	The stock's total return is expected to reach 15% or higher over the next 12 months.
Hold	The stock's total return is expected to be between negative 10% and positive 15% over the next 12 months.
Reduce	The stock's total return is expected to fall below negative 10% over the next 12 months.

The total expected return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net dividend yields of the stock. Stock price targets have an investment horizon of 12 months.

Sector Ratings Definition:

Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.

Country Ratings Definition:

Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.

Analyst Certification

The analyst who is primarily responsible for the content of this report, in whole or in part, certifies that with respect to the securities or issuer covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject, securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by the analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the securities covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the securities covered in this research report three business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong-listed companies covered in this report; and (4) have any financial interests in the Hong Kong-listed companies covered in this report.

#11